Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jul 11;8(28):46436-46448.
doi: 10.18632/oncotarget.17502.

Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy: a systematic review and meta-analysis

Xue Shao  1   2   3 , Bingjue Li  1   2   3 , Luxi Cao  1   2   3 , Ludan Liang  1   2   3 , Jingjuan Yang  1   2   3 , Yucheng Wang  1   2   3 , Shi Feng  1   2   3 , Cuili Wang  1   2   3 , Chunhua Weng  1   2   3 , Xiujin Shen  1   2   3 , Hong Jiang  1   2   3 , Jianghua Chen  1   2   3
Affiliations
Meta-Analysis

Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy: a systematic review and meta-analysis

Xue Shao et al. Oncotarget. .

Abstract

The 2009 Oxford Classification of immunoglobulin A (IgA) nephropathy (IgAN) identifies four histological features as predictors of renal prognosis: mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy/interstitial fibrosis (T). However, the clinical and prognostic significance of crescent formation still remains controversial. Therefore, we performed a meta-analysis to evaluate the association between crescents and kidney outcome in IgAN. A total of 20 studies published from January 2009 to July 2016 involving 5,285 patients were included after systematic searches of PubMed and EMBASE databases. Pooled results showed that crescent lesions were associated with kidney failure (HR, 1.93; 95% CI, 1.49-2.50; P < 0.001). IgAN patients with crescents had lower eGFR levels (SMD, -0.21; 95% CI, -0.40--0.03; P = 0.023); higher proteinuria levels (SMD, 0.87; 95% CI, 0.11-1.63; P = 0.024); a larger number of patients with M1 (RR, 1.22; 95% CI, 1.07-1.40; P = 0.003), E1 (RR, 4.83; 95% CI, 3.04-7.66;P < 0.001), S1 (RR, 1.76; 95% CI, 1.11-2.80; P = 0.016) and T1/2 (RR, 2.74; 95% CI, 2.10-3.57; P < 0.001) lesions; and received immunosuppressive therapy more frequently (RD, 0.17; 95% CI, 0.11-0.23; P < 0.001). Our results suggest that crescent formation represents an efficient prognostic factor associated with progression to kidney failure and thus could be considered into the new Oxford Classification.

Keywords: Immunoglobulin A (IgA) nephropathy; crescent lesions; meta-analysis; oxford classification.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1. Flow chart for study selection
562 articles were downloaded as potential studies, and 162 publications of which were excluded due to duplication. After detailed evaluation, 380 more were excluded according to the inclusion and exclusion criteria. Eventually, 20 studies involving a total of 5,285 patients were included.
Figure 2
Figure 2. Hazard ratios (HR) for kidney failure for patients with versus without cellular/fibrocellular crescents
The IgAN patients with crescents had an increased risk of worse kidney outcome (C0 as reference; HR, 1.93; 95% CI, 1.49-2.50; P < 0.001), with no evidence of heterogeneity (I2 = 40.9%; P = 0.076).
Figure 3
Figure 3. Standard mean differences (SMD) for the level of eGFR for patients with versus without cellular/fibrocellular crescents
The IgAN patients with crescents had decreased eGFR levels (SMD, -0.21; 95% CI, -0.40--0.03; P = 0.023), with high heterogeneity (I2 = 78%; P < 0.001).
Figure 4
Figure 4. Standard mean differences (SMD) for the level of proteinuria for patients with versus without cellular/fibrocellular crescents
The IgAN patients with crescents had increased proteinuria levels (SMD, 0.87; 95% CI, 0.11-1.63; P = 0.024), with high heterogeneity (I2 = 89.2%; P < 0.001).
Figure 5
Figure 5. Risk differences (RD) for immunosuppressive therapy for patients with versus without cellular/fibrocellular crescents
The IgAN patients with crescents were more likely received immunosuppressive treatment (RD, 0.17; 95% CI, 0.11-0.23; P < 0.001), with no evidence of heterogeneity (I2 = 48.9%; P = 0.118).
Figure 6
Figure 6. Risk differences (RD) for RASBs treatment for patients with versus without cellular/fibrocellular crescents
There were no significant differences in the use of RASBs between the two groups (RD, 0.09; 95% CI, -0.01-0.19; P = 0.071), with evidence of heterogeneity (I2 = 69.0%; P = 0.040).
Figure 7
Figure 7. Risk ratios (RR) for other lesions for patients with versus without cellular/fibrocellular crescents
The numbers of patients with M1 (RR, 1.22; 95% CI, 1.07-1.40; P = 0.003), E1 (RR, 4.83; 95% CI, 3.04-7.66; P < 0.001), S1 (RR, 1.76; 95% CI, 1.11-2.80; P = 0.016), and T1/2 (RR, 2.74; 95% CI, 2.10-3.57; P < 0.001) were significantly larger in the IgAN patients with crescents, with no evidence of heterogeneity in M, E, T (M1, I2 = 24.0%; P = 0.267; E1, I2 = 64.8%; P = 0.059; I2 = 17.4%; P = 0.271), and high heterogeneity in S1 (I2 = 87.4%; P < 0.001). M1 defined as M score > 0.5, E1 defined as any E lesion present, S1 defined as any S lesion present, T1/2 defined as > 25% but < 50% and > 50% T lesion present.
Figure 8
Figure 8. Funnel plot for testing the publication bias of the 11 studies evaluating the association between crescent formation and kidney survival
No obvious publication bias affected the association of crescent formation in IgAN with kidney survival. HR: hazard ratio; s.e.: standard error.
See this image and copyright information in PMC

References

    1. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526–32. - PubMed
    1. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37. doi: 10.1053/ajkd.2000.8966. - DOI - PubMed
    1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14. doi: 10.1056/NEJMra1206793. - DOI - PubMed
    1. Roufosse CA, Cook HT. Pathological predictors of prognosis in immunoglobulin A nephropathy: a review. Curr Opin Nephrol Hypertens. 2009;18:212–9. doi: 10.1097/MNH.0b013e328329605c. - DOI - PubMed
    1. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546–56. doi: 10.1038/ki.2009.168. - DOI - PubMed